Lakefront Biotherapeutics revenue and financials
€25.90Change from previous close: −1.97%Absolute change: −€0.52
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -257 | -320 | -406 | -501 | — |
| Depreciation and amortization | 55.9 | 45.5 | 43.6 | 65.6 | — |
| Capital expenditure | -13.9 | -82.1 | -19.3 | -36.9 | — |
| Investing cash flow | 289 | 221 | 71.2 | -1,246 | — |
| Financing cash flow | -3.3 | -4.9 | -5.0 | -1.5 | — |
| Debt repaid | -3.3 | -4.9 | -6.8 | -8.2 | — |
| Effect of exchange rates | -4.5 | 1.8 | -1.5 | 22.3 | — |
| Net change in cash | 28.1 | -104 | -340 | -1,748 | — |
| Free cash flow | -271 | -402 | -425 | -537 | — |